Rifabutin-d6

C[C@H]1/C=C/C=C(C)\C(/N=C2C(O)=C3C(C4=C(O[C@@](O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@H]1O)(C)C4=O)C(C)=C3O)=C5C/2=NC6(CCN(CC(C([2H])([2H])[2H])C([2H])([2H])[2H])CC6)N5)=O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Review Article: Rifabutin in the Treatment of Refractory Helicobacter pylori Infection 
 J. P. Gisbert, X. Calvet Issue Alimentary Pharmacology & Therapeutics Volume 35, Issue 2, pages 209-221, January 2012|[3]Vourvahis M, Davis J, Wang R, Layton G, Choo HW, Chong CL, Tawadrous M.
 Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-o-desacetyl-rifabutin in healthy subjects.
 Antimicrob Agents Chemother. 2012 Aug;56 (8) :4303-9.|[4]Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X.
 Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.
 Aliment Pharmacol Ther. 2012 Apr;35 (8) :941-7. doi: 10.1111/j.1365-2036.2012.05053.x.|[5]Gisbert JP, Calvet X.
 Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.
 Aliment Pharmacol Ther. 2012 Jan;35 (2) :209-21. doi: 10.1111/j.1365-2036.2011.04937.x.|[6]Horne DJ, Spitters C, Narita M.
 Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
 Int J Tuberc Lung Dis. 2011 Nov;15 (11) :1485-9, i.